Celgene notches positive Otezla data in scalp psoriasis as it guns for market expansion
admin 9th October 2018 Uncategorised 0An FDA approval for Otezla in scalp psoriasis could bring Celgene closer to meeting analysts’ expectations for peak product sales of $2 billion. But the company will have to come up with a good strategy for dealing with a raft of challenges, from payer pushback to competition from biosimilar versions of older drugs.
More: Celgene notches positive Otezla data in scalp psoriasis as it guns for market expansion
Source: fierce